CBD and Schizophrenia Cognition: Why the Multiple-Testing Threshold Matters

A CBD–amisulpride trial reported nominal cognitive improvements, but the paper’s stated multiple-testing threshold was much stricter than p = 0.05. The results should not be summarized from the title alone.

An exploratory secondary analysis

Forty-two patients with acute schizophrenia were randomized to CBD or amisulpride for four weeks. Cognition was a secondary objective. Twenty-nine completed two cognitive assessments, and fewer completed every test.

This was an active-controlled comparison, not a placebo-controlled test of cognitive benefit. Improvement over time could include effects of clinical recovery, repeated testing and the inpatient setting.

Nominal significance and corrected significance

The authors specified that Bonferroni correction would require p below 0.0004. Reported within-group p-values for improvements such as visual memory and processing speed were above that threshold, even when below 0.05.

These findings can be described as exploratory signals with effect-size estimates. They should not be presented as all meeting the paper’s corrected criterion. The study also found no post-treatment cognitive differences between groups.

No difference does not prove equivalence

Failing to detect a difference in a small study is not a formal equivalence demonstration. Wide uncertainty and incomplete outcome data can conceal clinically meaningful differences.

Likewise, no relevant correlation with symptom changes or serum anandamide does not prove that every possible mechanism is independent of those variables. Absence of a detected correlation and proof of no causal pathway are different propositions.

The useful scientific question is which cognitive endpoint, analysis set and significance standard supports a claim. This trial cannot establish a general cognitive-enhancement effect of CBD or certify functional recovery in a particular patient.

Related analysis

See our analysis of why a measured cannabinoid result is not a functional conclusion.

Primary research

F. Markus Leweke and colleagues. Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. Frontiers in Pharmacology. DOI: 10.3389/fphar.2021.614811.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

THC/CBD Rat Brain Imaging: Why Dose and Anesthesia Limit ‘Protection’ Claims

A rat imaging study found distinct THC, CBD and combination patterns in connectivity and blood flow. The mixture moderated some THC-associated findings, but the experiment does not establish a human protective ratio or a validated impairment test. The exposures were not identical across arms Adult male rats received injected THC,…

Spread the love

Read Article: THC/CBD Rat Brain Imaging: Why Dose and Anesthesia Limit ‘Protection’ Claims

Matching Plasma THC Peaks Did Not Match Brain Exposure Across Routes in Rats

Comparable peak circulating THC did not produce identical brain and metabolite profiles after injected versus inhaled THC in rats. Matching one parent-drug concentration therefore did not make the two routes biologically interchangeable. A direct route comparison Adult male and female Sprague–Dawley rats received intraperitoneal THC or a 15-minute inhalation exposure….

Spread the love

Read Article: Matching Plasma THC Peaks Did Not Match Brain Exposure Across Routes in Rats

A Urine Paper Titled ‘THC Quantification’ Actually Targeted THC-COOH

The analyte in a laboratory method matters more than shorthand in its title. A paper titled as urinary THC quantification describes a confirmatory method for THC-COOH, the carboxy metabolite. That is not a measurement of active parent THC or contemporaneous impairment. What the method measured The investigators developed solid-phase extraction…

Spread the love

Read Article: A Urine Paper Titled ‘THC Quantification’ Actually Targeted THC-COOH

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us